Lung Non-Squamous Non-Small Cell Cancer

P2, N=3, Active, not recruiting, Liza Villaruz, MD | Recruiting --> Active, not recruiting | N=35 --> 3 | Trial completion date: Apr 2029 --> Aug 2026 | Trial primary completion date: Sep 2027 --> Aug 2024

P2, N=40, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting | N=147 --> 40

P3, N=516, Recruiting, Shanghai JMT-Bio Inc.

P2, N=22, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, the decision is not related to any safety concern.

P2, N=90, Not yet recruiting, Merck Sharp & Dohme LLC

Our results indicate that 14-gene RNA-level assay is correlated with specific genetic mutations, including TP53, KRAS, and LRP1B. These insights provide a stronger foundation for integrating molecular risk assessment with clinical and imaging data, offering more comprehensive information to guide more targeted and effective adjuvant therapy strategies in the future management of lung cancer.

P1, N=177, Recruiting, BeiGene | Not yet recruiting --> Recruiting

P1, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025

P2, N=40, Not yet recruiting, Virginia Commonwealth University

In a first-in-human phase 1-2a study (GDFATHER-1/2a trial, NCT04725474 ), patients with advanced cancers refractory to anti-PD-1 or anti-PD-L1 therapy (termed generally as anti-PD-1/PD-L1 refractoriness) were treated with the neutralizing anti-GDF-15 antibody visugromab (CTL-002) in combination with the anti-PD-1 antibody nivolumab. Increased levels of tumour infiltration, proliferation, interferon-γ-related signalling and granzyme B expression by cytotoxic T cells were observed in response to treatment. Neutralizing GDF-15 holds promise in overcoming resistance to immune checkpoint inhibition in cancer.

P2/3, N=542, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: May 2027 --> Dec 2025

P2, N=401, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2024 --> Sep 2025

P3, N=363, Recruiting, OSE Immunotherapeutics | Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Dec 2024

P1/2, N=199, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting | Trial completion date: Apr 2026 --> Mar 2028 | Trial primary completion date: Apr 2026 --> Mar 2028

P3, N=756, Not yet recruiting, Immutep S.A.S.

Individuals with resectable NSCLCs had significantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy, objective response rate to non-objective response rate, and programmed death-ligand 1≥1% to programmed death-ligand 1 ≤1%, however, no significant difference was found between stage III and stage I-II, and squamous cell cancer and non-squamous cell cancer. To validate this discovery, more research is required since most of the selected studies had a low sample size, and caution must be implemented when interacting with its values.

P2, N=120, Not yet recruiting, Tasly Biopharmaceuticals Co., Ltd.

P1, N=77, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed

P1/2, N=139, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

P1, N=87, Recruiting, Arcus Biosciences, Inc. | Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Aug 2025 --> Mar 2026

P2, N=40, Recruiting, First People's Hospital of Hangzhou

P2, N=20, Recruiting, Jair Bar, M.D., Ph.D. | Not yet recruiting --> Recruiting

P2, N=72, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Nov 2024

P3, N=432, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

P3, N=1350, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> Nov 2027 | Trial primary completion date: Feb 2027 --> Nov 2027

A high ISAC was identified as a significant predictor for virtually no added value of platinum-doublet chemotherapy for first-line ICI treatment in low PD-L1-expressing nsqNSCLC. Our findings may help refine personalized therapeutic strategies for nsqNSCLC, thereby improving efficacy and reducing undue toxicity.

Camrelizumab plus carboplatin and pemetrexed as first-line therapy continued to demonstrate long-term OS benefit over carboplatin and pemetrexed, with manageable toxicity. Patients who completed 2 years of camrelizumab had enduring response and impressive OS. Current 5-year updated analysis further supports camrelizumab plus carboplatin and pemetrexed as a standard-of-care for previously untreated advanced non-squamous NSCLC without EGFR/ALK alterations.

P2, N=35, Recruiting, Liza Villaruz, MD | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Sep 2025 --> Sep 2027

P3, N=160, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2025

P1, N=254, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, The decision is not related to any safety concern.

P3, N=927, Recruiting, Amgen | Trial completion date: Jun 2026 --> Oct 2027 | Trial primary completion date: Jun 2026 --> Oct 2027

This case demonstrates the efficacy of envafolimab combined with endostar in the treatment of advanced NSCLC. This regimen enhances treatment safety and patient compliance, potentially offering a novel therapeutic option for patients with advanced NSCLC characterized by low PD-L1 expression and negative driver gene mutations.

No abstract available

No abstract available

P3, N=160, Not yet recruiting, Merck Sharp & Dohme LLC

P2, N=180, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2028 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2024

P2, N=31, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, the decision is not related to any safety concern.

P1, N=6, Recruiting, Second Xiangya Hospital of Central South University | Not yet recruiting --> Recruiting

P3, N=650, Active, not recruiting, Prestige Biopharma Limited | Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024

There is no evidence that perioperative immunotherapy is better than neoadjuvant immunochemotherapy in EFS. Patients with non-squamous disease, PD-L1 expression more than 50%, or stage III disease can try the neoadjuvant immunochemotherapy mode.

The results of our study are highly encouraging, as they revealed a significant correlation between immunohistochemical biomarkers, therapeutic regimens, and prognosis. These findings indicate that our immunohistochemical detection panel has great potential for facilitating customization of therapeutic regimens to improve patient care. The insights gained from this study could help clinicians optimize treatment protocols and ultimately enhance clinical outcomes.